Tarsus Pharmaceuticals, Inc. (TARS) vs Xenon Pharmaceuticals Inc. (XENE)

Tarsus Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Tarsus Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. are of similar size ($3.7B and $3.6B). Tarsus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 105.2% against −8.15%. Xenon Pharmaceuticals Inc. has the higher net margin (0.00% vs −7.67%) and the lower return on invested capital (−88.5% vs 0.00%). Across the 17 metrics below, Tarsus Pharmaceuticals, Inc. leads on 11 and Xenon Pharmaceuticals Inc. on 6.

Valuation

Metric TARS XENE Biotechnology median
P/E n/m n/m 7.88
P/S 5.42 217.29 11.47
P/B 9.47 2.96 2.52
Price to free cash flow 69.88 n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 4.80 162.98 10.73
Earnings yield (1.44%) (12.83%) (28.84%)
Free cash flow yield 1.43% (9.20%) (23.03%)

Profitability

Metric TARS XENE Biotechnology median
Gross margin 93.28% 28.40% 65.16%
Operating margin (8.00%) 0.00% 0.00%
Net margin (7.67%) 0.00% 0.00%
Free cash flow margin 9.24% 0.00% 0.00%
Return on equity (13.68%) (43.62%) (57.72%)
Return on assets (8.40%) (41.54%) (49.22%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric TARS XENE Biotechnology median
Revenue growth (TTM) 105.17% (8.15%) 5.64%
EPS growth (last fiscal year) 48.21% (44.85%) —
Revenue growth, 5-year CAGR — 89.00% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TARS XENE Biotechnology median
Debt to equity 0.21 0.00 0.00
Current ratio 3.20 21.02 4.73
Net debt to EBITDA 4.66 1.48 0.96

Dividend

Metric TARS XENE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric TARS XENE Biotechnology median
Market cap 3.55b 3.73b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack